Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and ALS, are characterized by aggregates of proteins. Many companies have tried to target the disassembly of these protein aggregates; however, few have made progress using this approach, until now. Cambridge, MA-based NeuroPhage Pharmaceuticals just reported positive results in a pre-clinical study using their anti-protein aggregate therapy, NPT001. Neurophage tested NPT001 in a pre-clinical model of Parkinson’s disease. In this model, NPT001, was able to clear the -synuclein protein aggregates, as well as restore normal function to neurons. The studies were performed in the laboratory of Dr. Eliezer Masliah, a professor at the University of California San Diego. NeuroPhage is one of the newest teams competing for the $1M ALS Treatment Prize, and hopefully, they will reproduce this positive result with NPT001 in ALS!
Click here to read more.Share this: